362 related articles for article (PubMed ID: 26908152)
21. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
[TBL] [Abstract][Full Text] [Related]
22. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy.
Sachdeo RC; Sachdeo SK; Walker SA; Kramer LD; Nayak RK; Doose DR
Epilepsia; 1996 Aug; 37(8):774-80. PubMed ID: 8764818
[TBL] [Abstract][Full Text] [Related]
23. Estimation of apparent clearance of valproic acid in adult Saudi patients.
Alqahtani S; Alandas N; Alsultan A
Int J Clin Pharm; 2019 Aug; 41(4):1056-1061. PubMed ID: 31222537
[TBL] [Abstract][Full Text] [Related]
24. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
Contin M; Riva R; Albani F; Avoni P; Baruzzi A
Ther Drug Monit; 2002 Jun; 24(3):332-7. PubMed ID: 12021622
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of carbamazepine in adults with epilepsy.
Graves NM; Brundage RC; Wen Y; Cascino G; So E; Ahman P; Rarick J; Krause S; Leppik IE
Pharmacotherapy; 1998; 18(2):273-81. PubMed ID: 9545146
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.
Falcão A; Fuseau E; Nunes T; Almeida L; Soares-da-Silva P
CNS Drugs; 2012 Jan; 26(1):79-91. PubMed ID: 22171585
[TBL] [Abstract][Full Text] [Related]
27. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
Goto S; Seo T; Hagiwara T; Ueda K; Yamauchi T; Nagata S; Ando Y; Ishitsu T; Nakagawa K
J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
[TBL] [Abstract][Full Text] [Related]
28. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data.
Blanco-Serrano B; Otero MJ; Santos-Buelga D; García-Sánchez MJ; Serrano J; Domínguez-Gil A
Biopharm Drug Dispos; 1999 Jul; 20(5):233-40. PubMed ID: 10594867
[TBL] [Abstract][Full Text] [Related]
29. Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis.
Milovanovic JR; Jankovic SM
Int J Clin Pharmacol Ther; 2011 Jul; 49(7):428-36. PubMed ID: 21726493
[TBL] [Abstract][Full Text] [Related]
30. Cross-sensitivity of skin rashes with antiepileptic drug use.
Hirsch LJ; Arif H; Nahm EA; Buchsbaum R; Resor SR; Bazil CW
Neurology; 2008 Nov; 71(19):1527-34. PubMed ID: 18981374
[TBL] [Abstract][Full Text] [Related]
31. Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy.
Kowalik A; Rimpau W; Adam H; Kühn F; van Oene J; Schreiner A; Bogdanow M; Schauble B;
Acta Neurol Scand; 2008 Mar; 117(3):159-66. PubMed ID: 18218062
[TBL] [Abstract][Full Text] [Related]
32. Carbamazepine metabolism in humans: effect of concurrent anticonvulsant therapy.
Ramsay RE; McManus DQ; Guterman A; Briggle TV; Vazquez D; Perchalski R; Yost RA; Wong P
Ther Drug Monit; 1990 May; 12(3):235-41. PubMed ID: 2112276
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age.
Girgis IG; Nandy P; Nye JS; Ford L; Mohanty S; Wang S; Ochalski S; Eerdekens M; Cox E
Epilepsia; 2010 Oct; 51(10):1954-62. PubMed ID: 20880232
[TBL] [Abstract][Full Text] [Related]
34. Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data.
Battino D; Croci D; Rossini A; Messina S; Mamoli D; Perucca E
Clin Pharmacokinet; 2005; 44(4):407-16. PubMed ID: 15828853
[TBL] [Abstract][Full Text] [Related]
35. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.
McKee PJ; Blacklaw J; Forrest G; Gillham RA; Walker SM; Connelly D; Brodie MJ
Br J Clin Pharmacol; 1994 Jan; 37(1):27-32. PubMed ID: 8148215
[TBL] [Abstract][Full Text] [Related]
36. Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication.
Kong ST; Lim SH; Chan E; Ho PC
J Clin Pharmacol; 2014 Feb; 54(2):225-33. PubMed ID: 23996245
[TBL] [Abstract][Full Text] [Related]
37. Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data.
Messina S; Battino D; Croci D; Mamoli D; Ratti S; Perucca E
Epilepsia; 2005 Mar; 46(3):372-7. PubMed ID: 15730534
[TBL] [Abstract][Full Text] [Related]
38. Clinical validation and implications of dried blood spot sampling of carbamazepine, valproic acid and phenytoin in patients with epilepsy.
Kong ST; Lim SH; Lee WB; Kumar PK; Wang HY; Ng YL; Wong PS; Ho PC
PLoS One; 2014; 9(9):e108190. PubMed ID: 25255292
[TBL] [Abstract][Full Text] [Related]
39. A model for estimating individualized valproate clearance values in children.
Botha JH; Gray AL; Miller R
J Clin Pharmacol; 1995 Oct; 35(10):1020-4. PubMed ID: 8568010
[TBL] [Abstract][Full Text] [Related]
40. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K
Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
